Please enter verification code
Prostate carcinoma: correlation of histopathology with serum prostate specific antigen
Science Journal of Clinical Medicine
Volume 4, Issue 4-1, July 2015, Pages: 1-5
Received: Jan. 14, 2015; Accepted: Jan. 19, 2015; Published: Aug. 3, 2015
Views 6232      Downloads 239
Deepika Gurumurthy, Department of Pathology, Apollo BGS, Mysore, India
Rangaswamy Maggad, Department of Pathology, JSS Medical College and Hospital, Mysore, India
Sapna Patel, Department of Pathology, JSS Medical College and Hospital, Mysore, India
Article Tools
Follow on us
Prostate Specific Antigen (PSA) is the first line test in screening of prostate cancer. The increase in PSA depends on differentiation of tumour cells. Gleason grading is one of the most powerful predictors of biological behaviour and influential factors used to determine treatment. PSA, when combined with Gleason score and clinical stage, improves the prediction of pathological stage for prostate carcinoma. Aims of this study were to study the histopathological features and Gleason grading in Prostatic Carcinoma and to correlate pretreatment PSA levels with Gleason grade. The study was undertaken in a tertiary care hospital over a period of two years.Fifty one cases of prostatic carcinoma were studied. Grading done by Gleason grading system, was correlated with serum PSA levels. Software statistical package for social sciences (SPSS), version 16 was used. P value < 0.05 was considered significant. Patients were aged predominantly between 60 to 70 yrs. Majority (66.7%) had poorly differentiated adenocarcinoma. 84.3% had high values of PSA (>10ng/ml). 5.9 % had PSA value in normal range (< 4 ng/ml). Though there was a comparative increase in PSA level with increase in Gleason grade, it was not statistically significant (‘p’ value = 0.75). To conclude, a proportion of tumours with Gleason score 8-10 are so poorly differentiated that they produce relatively little PSA. Refinement in estimation and interpretation of PSA values may be considered to improve the sensitivity and specificity of PSA. Gleason grading is a better predictor of biological behaviour of prostate cancer.
Gleason Grade, Prostate Cancer, PSA
To cite this article
Deepika Gurumurthy, Rangaswamy Maggad, Sapna Patel, Prostate carcinoma: correlation of histopathology with serum prostate specific antigen, Science Journal of Clinical Medicine. Special Issue: Latest Different Concepts of Gynaecology. Vol. 4, No. 4-1, 2015, pp. 1-5. doi: 10.11648/j.sjcm.s.2015040401.11
[1] Accessed on 29/08/2013.
Dubey D. The early use of prostate specific antigen for early detection of cancer prostate in India: Is it justified? Indian J Urol 2009;25:177-84.
Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003;169:445-57.
Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Does prostate growth confound PSA velocity? Data from the Baltimore longitudinal study of aging.J Urol 2008;180:1314-7.
Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
Mawakyoma H A, Mabandi J L. Prostate cancer; Correlation of Gleason’s score and pretreatment prostate specific antigen in patients. Professional Med J 2010;17:235-40.
Jackson LA , McGrowder DA, Lindo RA. Prostate specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in western Jamaica. Asian Pacific J Cancer Prev 2012;13:1453–6.
Okolo CA, Akinosun OM, Shittu OB, Olaopa OO, Okeke LI, Akang EU. Correlation of serum PSA and Gleason score in Nigerian men with Prostate Cancer. African journal of urology 2008;14:15-22.
Shirley SE, Escoffery CT, Sargeant LA, Tulloch T. Clinicopathological features of prostate cancer in Jamaican men. BJU International 2002; 89:390-5.
Zivkovic S.Correlation between prostate specific antigen and histopathological difference of prostate carcinoma. ArchOncol 2004;12:148-51.
Mulay K, Swain M, Jaiman S. Gleason’s scoring of prostatic carcinoma: Impact of a web based tutorial on inter and intra observer variability. Indian J Pathol Microbiol 2008;51:22-5.
Corcoran NM, Hong MKH, Casey RG. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.BJU International 2010;108:E202-10.
Horninger W, Volgger H, Rogatsch H, Strohmeyer D, Steiner H, Hobisch A et al. Predictive value of total and percent free PSA in high grade prostatic intraepithelial lesion: Results of tyrol prostate specific antigen screening project. J Urol 2001;165:1143-5.
Zynger DL, Yang X. High grade prostatic intraepithelial neoplasia of the prostate: The precursor lesion of Prostate Cancer.Int J Clin Exp Pathol 2009;2:327-38.
Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007;109:13-24.
Abdellatif J, Hajji F, Elonodo JC, Ghadouane M, Ameur A, Abbar M. Update the Indicator Role of Serum PSA Level and Gleason Score of the Biopsy for the Presence of Bony Metastases: Bone Scan Findings in a North African Ethnic Group. J Cancer Sci Ther 2011;3:112-5.
McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P. Outcomes in patients with Gleason score 8-10 prostate cancer : relation to preoperative PSA level. BJU International 2011;109:1764-9.
Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000;163:1739–42.
Shih WJ, Gross K, Mitchell B, Collins J, Wierzbinski B, Maqoun S et al. Prostate adenocarcinoma using Gleason scores correlates with prostate specific antigen and prostate acid phosphatase measurements. J Natl Med Assoc 1992;84:1049-50.
Schroder FH, Crvijsen VD, Koeter I, De Koning HJ,Vis AN, Hoedemaeker RF. Prostate cancer detection at low prostate-specific antigen. J Urol 2000;163:806-12.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186